Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.

Date publication

février 2016

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUILLAULT Gérard

Tous les auteurs :
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N, Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V, Wouters C, Angioloni S, Martini A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26645190

Résumé

Most data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomised case series. We aimed to compare, in a randomised trial, the efficacy and safety of prednisone alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset juvenile dermatomyositis.

Mots clés

Adolescent, Analysis of Variance, Anti-Inflammatory Agents, administration & dosage, Child, Child, Preschool, Cyclosporine, administration & dosage, Dermatologic Agents, administration & dosage, Dermatomyositis, drug therapy, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Kaplan-Meier Estimate, Male, Methotrexate, administration & dosage, Prednisone, administration & dosage, Treatment Outcome

Référence

Lancet. 2016 Feb;387(10019):671-8